Skip to content
Screener

Alto Neuroscience ANRO Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

EPS-$0.45Beat by $0.11
EPS estimate-$0.56

Next report

Nov 11, 2026 (in 2 months)
EPS estimate-$0.67

Financials

Q4 2025

Income statement

See full
Operating income-$17.1M-0.3%
Net income-$16.2M-6.5%
EPS (diluted)-$0.45+19.6%

Balance sheet

See full
Cash & equivalents$177.0M+4.9%
Total debt$21.7M+38.9%
Total equity$151.1M-0.2%
Total assets$184.7M+4.0%

Cash flow

See full
Operating cash flow-$11.5M+11.6%
Free cash flow-$11.5M+14.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$552.98M+385%
Enterprise value$397.73M+1,120%

Returns & leverage

See full
Return on equity-41.8%—
Debt / equity0.1×0.0×
Current ratio15.7×-1.2×

FAQ

When did Alto Neuroscience report Q4 2025 earnings?
Alto Neuroscience (ANRO) reported Q4 2025 earnings on March 16, 2026 before market open.
What were Alto Neuroscience's Q4 2025 revenue and EPS?
Alto Neuroscience reported eps of $-0.45 for Q4 2025.
Did Alto Neuroscience beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.56 by $0.11.
How did Alto Neuroscience's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 19.6% from $-0.56.
Where can I find Alto Neuroscience's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001999480-26-000001) and the 10-K periodic report (0001999480-26-000002) directly on SEC EDGAR. The filing index links above go to sec.gov.